Separate terms with OR to return results that match either term.
 
Clear All
700 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year (Ascending) FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
S0115 Bortezomib Velcade 3.5 mg Chemotherapy Proteasome Inhibitor 26S No 2003 Jan. 1, 2004 Dec. 31, 2004 No Longer Used
A9534 Tositumomab Bexxar, Iodine i-131 Tositumomab, therapeutic per MC Immunotherapy, Radiopharmaceutical Radioimmunotherapy CD20 No 2003 2014 July 1, 2003 In Use
A9545 Tositumomab Bexxar, Iodine i-131 Tositumomab, therapeutic Per treatment dose Immunotherapy, Radiopharmaceutical Radioimmunotherapy CD20 No 2003 2014 Jan. 1, 2006 In Use
C9216 Abarelix Plenaxis 10 mg Hormonal Therapy Androgen Receptor Inhibitor LHRH antagonist No 2003 2005 Jan. 1, 2005 No Longer Used
J0128 Abarelix Plenaxis 10 mg Hormonal Therapy Androgen Receptor Inhibitor LHRH antagonist No 2003 2005 Jan. 1, 2005 No Longer Used
S0165 Abarelix Plenaxis 100 mg Hormonal Therapy Androgen Receptor Inhibitor LHRH antagonist No 2003 2005 Jan. 1, 2005 No Longer Used
NA Aprepitant Emend 125 mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Yes 2003 In Use
NA Aprepitant Emend 80 mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Yes 2003 In Use
NA Aprepitant Emend 40 mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Yes 2003 In Use
J8501 Aprepitant Emend 5 mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Yes 2003 Jan. 1, 2005 In Use

Found 700 results in 1 millisecond — Export these results

The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.